Depleted uranium/Bone/Kidney/Distribution/ICP-MS.
INTRODUCTION
Depleted uranium (DU) is a by-product of uranium enrichment and has roughly 60-75% of the radioactivity of an equivalent amount of natural uranium due to the reduction of the percentage of radioactive isotopes ( 234 U and 235 U) from 0.72 and 0.006%, respectively, in natural uranium to 0.2 and 0.001%. [1] [2] [3] DU has not only military applications, but also a number of civilian applications due to its physical properties (e.g. high density, relatively abundant quantity and appropriate cost). For example, DU is employed as counterweights or ballasts in aircraft, radiation shields in medical equipment, containers for the transport of radioactive materials and chemical catalysts. DU has also been used in glassware, ceramics (as cooking and serving containers) and dentistry. [4] [5] [6] At present, the extensive use of DU results in the increase of interest on the possible effects on environment and health consequence. [7] [8] [9] As a kind of heavy metal with low level radioactivity, DU may enter the body principally via: (1) Inhalation through the respiratory tract, in a war particularly, DU shell can form a radioactive aerosol (account for about 80% of the shell body) in a high temperature reaction after explosion, and as a result, the war participants and the population around may be injured in the body due to the inhalation of the radioactive aerosol with DU. (2) Ingestion through the digestive tract, the fine particles of DU carried by wind float, scatter and contaminate the air, ground, water source or any object, and finally enter the human body through the food chain. (3) Embedded injury into wounds, a long retention in the body makes the DU fragments dissolved and absorbed, gradually transferred to some critical organs via body fluids, and produce chemical toxicity and/or radiotoxicity. 5, 6, 10, 11) Due to the similarity of chemical properties between DU and natural uranium, DU shows a toxic effect on the body similar to natural uranium. It has been reported in previous researches that after accidental inhalation, ingestion, or absorption through intact or wounded skin, natural uranium mainly deposited in the skeleton and in the kidneys, and may induce renal damage and inhibition of bone formation. [12] [13] [14] However, the biokinetics of uranium entering the body through DU-embedded wound received little attention and experimental data are needed. The current study was designed to determine the accumulation and distribution of uranium continuously liberated from DU fragments embedded in the gastrochnemius muscle of rats over the course of 360-d test, to simulate the behavior and consequence of injuries with DU fragments, in order to provide information that may be used in a health hazard assessment of DU-embedded injury.
MATERIALS AND METHODS

Chemicals
DU fragments were provided by China National Nuclear Corp., composed of 99.25% DU and 0.75% titanium by weight, with the uranium isotopes of 238 U (99.79%), 235 U (0.20%) and trace levels of 234 U. Each DU fragment was approximately 8 mm length × 2 mm width × 1 mm thickness in size (about 0.1 g DU), and it was immersed into dilute nitric acid and ethanol before the implantation. Ta fragments (Tantalum, Ta), used as control fragments with a mass similar to uranium, were provided by Ningxia Orient Tantalum Industry Co., Ltd., (batch number ST-506-0445). Uranium standard material (GBW04220 and GBW04222) were also obtained from China National Nuclear Corporation.
Experimental animals
Male Sprague-Dawley rats (6 weeks old at the beginning of the experiment) weighing approximately 200 g, were obtained from Experimental Animal Center of Fudan University, with certification No., SCXK(Shanghai) 2003-0002. At the beginning of the experiment, rats were quarantined and screened for diseases. Except during urine collection, all animals were housed in plastic Microisolator rat cages with hardwood chips as bedding. Commercial rodent chow and water were provided. All experimental procedures were approved by the Animal Care Committee of Fudan University.
After a 1-week adaptation period, a total of 132 male Sprague-Dawley rats were randomly assigned a treatment group and surgically implanted with DU or Ta fragments using methods previously described by Pellmar et al. 15) Rats were implanted with 0.1 g DU + 0.2 g Ta fragments, 0.2 g DU + 0.1 g Ta fragments, 0.3 g DU fragments or 0.3 g Ta fragments, respectively. All surgically implanted rats received 0.3 g fragments in the left gastrochnemius muscle. After implantation and suturing, the animals were fed with common rat feeds under the same conditions in Experimental Animal Center of Fudan University. 
Sample Collection
After urine was collected from each rat, individually housed for 24 h in metabolism cages and having continuous accessing to food and water, rats were euthanized by exsanguinations from carotid artery under anesthesia (22% ethylurethanm, 5 mL/kg). Blood samples were obtained from carotid artery and centrifuged for 5 min at 3000 × g to extract the serum. The following tissues were pooled among their respective treatment groups for analysis: kidney, liver, spleen, thyroid gland, lung, heart, testes, brain, tibia and gastrocnemius muscle (from right leg per animal). All samples including urine, serum and tissues were frozen and stored at -70°C until analysis.
Sample treatment
The tissue samples for the determination of uranium level were performed using wet acid digestion. About 1-2 g wet tissue sample was weighted out into a quartz crucible, 5 mL of nitric acid and 1 mL hydrogen peroxide were added to each crucible, which was then placed on a hot plate and set the temperature to about 150°C for several hours. Then, the samples were carefully heated to a higher temperature to evaporate the solution volume to approximately 0.5 mL. More addition of nitric acid and repeat this procedure would be required if retained residue still remained. Finally, an absolutely digested clear solution was transferred to a flask and diluted with deionized water to 10 mL volume. Serum and urine samples were directly diluted 20 times and 10 times, respectively, with 1% nitric acid (V/V) before measurement. While for the bone samples, about 1 g for each specimen, were placed in a muffle furnace at 300°C for 2 h and 600°C for another 4 h for incineration. After a cooling period, the residue was dissolved using about 1mL of nitric acid and 1mL deionized water, and the digested solution was finally transferred to a flask and diluted with deionized water to 25 mL volume. All reagents used were of the high pure grade. Water used for dilution was Milli Q (Millipore Corp., Millford, MA, USA) deionized water.
Measurement of uranium
Uranium determinations in wet-ashed tissues were performed by inductively coupled plasma-mass spectrometry (ICP-MS) using U.S.EPA Method 6020. 16) After proper dilution, a Thermo X-7 ICP-MS (Thermo Elemental Co., Ltd. USA) was employed for the determination of uranium isotopes and levels. The determination was performed by using the normal mode (Table 1) Table 1 ). The limit of detection (LOD) for uranium using ICP-MS was less than 0.001 ng/mL. Table 2 was the determination values of the 235 U/ 238 U isotope ratio of GBW04220 and GBW04222. Additionally, with regards to the DU fragments used in this experiment, the determination value of the 235 U/ 238 U isotope ratio was 0.00294 ± 0.00005, which was far below the value of natural abundance uranium, and was within the scope of isotope ratio from depleted uranium ( Table 2) .
Statistical analysis
The results of the uranium concentration in tissues, serum and urine are expressed as the mean ± standard error. Tissue uranium concentration for each organ was obtained from the content of uranium divided by the wet weight of the tissue and averaged for each experimental group at each time point. In all cases, five or six measurements for uranium concentration were included in the final averaged value. Data were analyzed by a one-way ANOVA. Following each one-way ANOVA, Dunnett's test was used to compare all treatments against the Ta-control. LSD test was used to compare all possible pairs. A P-value < 0.05 was considered significant.
RESULTS
Deaths and clinical observation
Of the 132 rats undergoing surgery, two animals died minutes after implantation surgery as a result of anesthesia injection with the analgesic ketamine hydrochloride (2 mL/ kg). Of the expired animals, one was implanted with 0.1 g DU + 0.2 g Ta fragments, and another was implanted with 0.3 g Ta fragments. No other deaths occurred during surgery.
Three rats died during the 360d post implantation surgery phase. Of the expired animals, one was implanted with 0.3 g Ta fragments, and two were implanted with 0.1 g DU + 0.2 g Ta fragments. No gross evidence of toxicity or inflammatory reaction was observed in any of these animals.
Redistribution of depleted uranium in the body
Immediately 1 day after the DU implantation, the ratios of 235 U/ 238 U in serum, kidney and liver samples decreased quickly down to 0.00297 ± 0.00015, 0.00293 ± 0.00032 and 0.00290 ± 0.00004, respectively, which were as the same value of 0.00294 ± 0.00005 for the embedded DU. From the above results, it was clearly confirmed that the embedded fragments of DU could redistribute throughout the body rapidly. Considering that, only the Uranium concentrations in all samples were measured at the following time points.
The changes of uranium level in the serum and urine
At 1 day after DU implantation, very low levels of uranium in serum were observed, but levels in the all dose groups significantly greater than that in Ta controls (Ta group, 0.45 ± 0.17 ng U/mL serum; low-dose group, 3.80 ± 0.94 ng U/ mL serum; medium-dose group, 4.58 ± 1.74 ng U/mL serum; high-dose group, 6.70 ± 4.50 ng U/mL serum). Uranium levels in the all dose groups increased significantly at the following 7 d and 30 d time points. The highest concentration of uranium in serum reached at 90 days post-implantation in the high-dose group, and at 30 days in the low-and medium-dose group (Fig. 1A) .
A significant accumulation was also observed in urine, and as early as 1 day after DU implantation, uranium levels in the urine obviously increased in the DU-implanted rats (Ta group, 1.48 ± 1.14 μg U/g Creatinine; low-dose group, 128.5 ± 27.4 μg U/g Creatinine; medium-dose group, 259.5 ± 88.2 μg U/g Creatinine; high-dose group, 385.4 ± 34.7 μg U/g Creatinine). Furthermore, as the primary means of uranium excretion, the uranium concentrations in the urine increased with dose and duration of exposure, and the highest concentration (about 3833 ± 628 μg U/g Creatinine) was observed at about 90 days post-implantation in the highdose group; thereafter, the uranium concentration in the urine decreased gradually, but maintained at a relatively high level even at 360 days after implantation (Fig. 1B) . Consequently, the uranium concentration in the urine was useful 
Uranium levels in tissues
Within 1 day after DU implantation, rats showed significant distribution of uranium to different tissues, especially in kidney: 3897 ± 780 ng U/g, 5503 ± 553 ng U/g and 6382 ± 768 ng U/g wet weight kidney, respectively, in the low-, medium-and high-dose group. A dose-dependent increase in uranium concentration was also observed for the tibia reaching 649.8 ± 99.3 ng U/g, 1160 ± 186 ng U/g and 1851 ± 276 ng U/g, respectively, in the low-, medium-and high-dose group. Uranium concentrations measured in other organs were also different, to varying degrees, from those measured in tissues from Ta-controls (detailed data not shown).
At 7, 30, 90, 180 and 360 days following implantation, uranium concentrations in all the DU implanted groups were significantly different from those measured in tissues from Ta-controls, and the highest concentration of uranium continued to be observed in kidney and bone. In other words, kidney and bone was main accumulation organ for uranium after DU-embedded injury, and there was high correlation between the implanted DU doses and uranium concentrations in the kidneys and bone (Figs. 2-6 ). Interestingly, in the early phase post DU implantation, the uranium concentrations in kidney were significantly higher than those in bone, however, great higher distribution was observed in bone at the later time points (Figs. 2-6 ).
In addition to kidney and bone, significant accumulations were also observed in other tissues, especially in spleen, liver and lung, and the uranium levels of these organs in all DU implanted groups were significantly higher than those in Ta controls (p < 0.01, Figs. 2-6) . Meanwhile, at 7 days after DU implantation, uranium concentrations in testes, thyroid gland and muscle also showed significant increase in the high-dose group, compared with those in the Ta controls (p < 0.01, Fig. 2 ). 
The dynamic change of Uranium levels in target organ
The uranium levels in kidney and bone, the major organ for uranium accumulation after DU implantation, increased with duration of exposure, and uranium concentrations of all dose groups were observed to reach maximum at 90 days post-implantation, thereafter, the uranium concentration decreased gradually but very slowly and still maintained at a relatively high level even at 360 days following DU implantation (Fig. 7) . For example, at 360 days post-implantation, the uranium concentrations in tibia were 6.92 ± 0.97 μg U/g, 16.35 ± 1.67 μg U/g and 21.64 ± 3.68 μg U/g in the low-, medium-and high-dose group animals, and the values in kidney tissues were 10.66 ± 1.10 μg U/g, 14.06 ± 1.28 μg U/g and 17.79 ± 2.87 μg U/g, respectively.
The changes of uranium concentration in additional tissues were analyzed. Uranium concentrations in spleen, liver, lung and heart were significantly greater than those in Ta controls. Similar to observations with kidney and bone, relatively high concentrations were observed at 90 days after DU implantation, and then decreased gradually and slowly (Figs. 8A-8D) . However, the uranium concentrations in these tissues were far lower than those in kidney and bone. At 90 days after DU implantation, the average concentrations in these tissues of the high-dose group were 44.48 ± 3.33 μg U/g in tibia, 36.50 ± 2.19 μg U/g in kidney, 1.44 ± 0.15 μg U/g in spleen, 0.53 ± 0.07 μg U/g in liver, 0.56 ± 0.04 μg U/g in lung and 0.15 ± 0.01μg U/g in heart tissue, respectively. 
DISCUSSION
The result of this study do indicate that the DU fragments used in this study dissolved in rat muscle over the 360-d test period and resulting free uranium transported to several tissues. Kidney and bone were the primary reservoirs for uranium redistributed from intramuscularly DU-embedded fragments, while uranium was detected in the urine with increasing concentration depending on DU fragment burden.
Depleted uranium is the by-product after 235 U is extracted from natural uranium, so its 235 U content is lower and specific activity is approximately 60-75% of that of natural uranium. 3, 17) As well known, uranium emits α, β and γ ionizing radiation, and α particles are the primary radiation hazard, which do pose a potential hazard after internal contamination. [18] [19] [20] It has been reported in previous studies that DU aggregation may cause impairment of systems such as kidney, lung and CNS. [21] [22] [23] [24] [25] However, the above conclusions were mainly based on the studies from the health effects of DU aerosol contamination by inhalation exposure on the battlefield , or animal experiments mimicking DU aerosol inhalation. For the behavior and consequence of injuries with DU fragments, because the DU residual fragments retaining in the body are highly insoluble and deliver a very small amount of uranium to the blood, the uranium could gradually transfer to and accumulate in target organ (such as kidneys and bone) and thus induce chemical toxicity and/or radiotoxicity, whereas partly excreted through urine. 10, 15, 26) It is well known that the assessment of toxicity resulting from radionuclide incorporation is partly based on the prediction of their biokinetics in the body. With regard to the occupational exposure of uranium miner, uranium was found in the highest concentrations in lung, kidney, bone, and liver. 27, 28) Animal studies have explored the distribution of uranium following experimental inhalation, injection, and ingestion. Following intravenous injection, uranium was quickly eliminated from the blood and redistributed to kidney, bone, liver and spleen, and excreted in urine. 29) While in the case of DU aerosol inhalation, just like intravenous injection, soluble DU particles were rapidly cleared from the blood and mainly accumulated in kidney and bone after absorbed into the blood, and then excreted through the urine, whereas for inhalation of hardly soluble DU dust, the highest uranium level appeared in the lung because of the local deposition of hardly soluble DU particles, which was significantly higher than other tissues including kidney and bone. 22, 30, 31) In other words, lung was the main target organ of uranium following inhalation of hardly soluble DU aerosol. 32) It has been revealed that after inhalation of DU aerosol with high concentration, rats mostly occurred pulmonary injury resulting in the degenerative change of the lung, pulmonary edema, pneumorrhagia and bronchopneumonia. 25) The result obtained from this study showed a pattern of uranium distribution different from that obtained from inhalation exposure of hardly soluble DU dust or aerosol. In the DU implanted rats, uranium concentrations in kidney and bone were significantly higher than those in other tissues throughout the experiment, that meant, kidney and bone were main reservoirs for the uranium, and other tissues such as lung, liver, spleen, testes, heart were also affected by DU fragments, however, they exhibited uranium levels far lower than those in kidney and bone (Figs. 2-6 ).
The interesting phenomenon was that, in the early phase post DU implantation, the uranium accumulation in kidney was more obvious than that in bone, whereas as the duration of implantation extended, particularly at 90 d post-implantation, the uranium concentration in bone was obviously higher than that in kidney (Figs. 2-6 ), which may be explained by the decline of kidney accumulation following constant excretion of uranium through the kidney and urine. Previous studies have shown that uranium in bone may be engaged in the calcification of bone, and the uranyl ion can displace calcium ion in bone matrix and bind to phosphates, which may cause about 80-90% uranium accumulation in the bone and blemish the bone structure. Consequently, once deposited in bone, uranium is hardly excreted from the body, 10, 33) and the uranium level in bone would descend at a slower rate than that in kidney.
As major organs responsible for the uranium accumulation after DU-embedded injury, kidney and bone showed increasing uranium concentrations as the duration of DU implantation extended, and the peak appeared at 90 d postimplantation. The uranium concentration in kidney and bone then decreased slowly, but still maintained at a high level even at up to 360 days post-implantation. As major organs where uranium accumulated in the body, kidney and bone had the most uranium deposited but hardly excreted after DU implantation, and accordingly sufficient attention should be paid to the studies on the harmful effects on bone metabolism and renal function induced by DU implantation.
The pattern of uranium excretion via urine at different time intervals post-implantation was observed. Because analysis of the urine volume (data not shown) suggested agedependent changes, the uranium concentration excreted during a 24-h period was adjusted and reassessed by creatinine. The present study demonstrated that the excretion of uranium in the urine of DU implanted rats significantly increased within 1 day after implantation, and uranium was excreted in the urine throughout the 360 days of the experiment (Fig. 1B) . Additionally, at different time point postimplantation, the uranium level in the urine always exhibited obvious correlation to the implanted DU dose, and there was a highest level in urinary uranium over the first 90 days, after which followed by a decreasing period, but the urinary uranium concentrations maintained relatively high even at up to 360 days after implantation (Fig. 1B) . In other words, uranium was persistently excreted via urine even at 360 days post-implantation, and the uranium excretion in the urine shared consistent pattern with the change of uranium level in tissues such as kidney and bone. In light of these findings, the urinary uranium level may be a sensitive indicator for measuring the pattern of uranium retention and the radiation dose in the body after DU-embedded injury.
Furthermore, from 7 days after DU implantation, the uranium concentration in the serum of DU-implanted rats had some increase but to a minimal extent (Fig. 1A) . This Phenomenon may be due to accumulation in the plasma rather than in the serum after entering in the body, for the heavy metals such as uranium and lead. 23, 34) Therefore, the uranium concentration in the plasma or the whole blood may be a superior indicator for the radioactive heavy metal such as uranium.
Similar to the other studies, 35) high concentrations of uranium were found in the liver of rats in all experimental groups in our present study (Fig. 8) , indicating liver was indeed a large pool for the accumulation of uranium. It was also interesting that uranium level in liver was higher than that in spleen only during the first 7 days after implantation (Fig. 8) , and from 30 days after implantation, uranium levels in spleen were at least 2 folds higher than those in liver (Fig.  8) . Such results may reflect a different route of uranium exposure (i.e., muscle-embedded fragments). Previous studies have shown that following inhalation of soluble DU aerosol or intravenous injection, the uranium was quickly absorbed and cleared via the blood. 26, 36) However, as for the hardly soluble uranium compounds, the uranium may be locally absorbed, distributed and cleared through the lymph nodes and the muscle also.
37) But, with very much regret, the uranium levels in the lymph nodes of DU-implanted rats were not analyzed in this study.
In summary, following implantation of rats with DU fragments, uranium is persistently excreted via urine even at 360 days post implantation, and the uranium excretion in the urine shares consistent pattern with the change of uranium level in kidney and bone. Otherwise, the propensity for internalized DU to translocation to several tissues, especially the kidney, skeletal tissue, spleen, liver, lung and testes, indicates that these tissues should be examined closely to determine if they are affected or altered as results of DU exposure in the case of embedded DU fragments. Influence of macrophages on microdistribution of inhaled UO2 aerosol in rat lung. Phys. Med. Biol. 27: 949-957.
